Cynata Therapeutics Limited(ASX: CYP) is a clinical-stage stem cell and regenerative medicine company. Cynata is focussed on the development and commercialisation of a proprietaryinduced pluripotent stem cell (iPSC)-based platform technology,Cymerus™. ...
Cynata’s CYP-004 MSC product is the subject of a Phase 3 clinical trial being sponsored by the University of Sydney and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant in addition to in-kind contributions from participating institutio...
Cynata Therapeutics's price close (unadjusted) is 0.23. View Cynata Therapeutics Ltd's (ASX:CYP) Price Close (Unadjusted) trends, charts, and more.
Cynata Therapeutics的折旧和摊销(损益表)于Juni 2021触及5年低点,是279.965千。 Cynata Therapeutics的折旧和摊销(损益表)于2021 (279.965千, -0.3%)减少、于2020 (280.732千, +0.3%)和2024 (280.732千, +0.3%)增加和于2022 (279.965千)和2023 (279.965千)持稳。 相比竞争对手,Cynata Therapeutics Ltd的折旧和...
过去5年,Cynata Therapeutics的每股净营运资本净额(nnwc)在June 2021达到了 0.18的峰值。 Cynata Therapeutics的每股净营运资本净额(nnwc)于June 2024触及5年低点,是0.028。 Cynata Therapeutics的每股净营运资本净额(nnwc)于2022 (0.15, -15.5%)、2023 (0.077, -47.7%)和2024 (0.028, -63.8%)减少和于2020 (0....
View Cynata Therapeutics Ltd (CYPOA) stock price, news, historical charts, analyst ratings, financial information and quotes on Futubull. Trade commission-free with the Futubull stock trading app.
CYP: Cynata Therapeutics Ltd Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for huma...+ VIEW MORE
Cynata Therapeutics's price close (unadjusted) is 0.24. View Cynata Therapeutics Ltd's Price Close (Unadjusted) trends, charts, and more.
CYPOA Cynata Therapeutics Ltd 添加自选 0.025 0.0000.00% 延时20分钟行情未开盘 01/07 15:45 (悉尼) 563.11万总市值0.00市盈率(静) 0.000最高价0.000最低价0股成交量0.000今开0.025昨收0.00成交额0.10052周最高0.00%换手率2.25亿总股本0.02252周最低--每股收益TTM439.06万流通值0.100历史最高0.00市盈率(静)...
过去5年,Cynata Therapeutics的pegy比率在kesäkuu 2023达到了 0.01的峰值。 Cynata Therapeutics的pegy比率于kesäkuu 2021触及5年低点,是-11.65。 Cynata Therapeutics的pegy比率于2020 (-0.55, -197.1%)、2021 (-11.65, +2,034.2%)和2024 (-0.09, -822.1%)减少和于2022 (-0.27, -97.7%)和2023 (0.01, ...